Ticker brief
OKYO
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
crowd 14d
-2.6σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-14 · now -0.55 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @proactive_x | C | -1.13 | 2 | +0.33 |
| @CrweWorld | C | · | 1 | +0.25 |
| @PrismMarketView | C | · | 1 | +0.10 |
| @PrismDM | A | -2.76 | 1 | +0.10 |
| @KampnerSam | A | -1.38 | 1 | -0.55 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @KampnerSam | -0.55 | Quantifies severe drawdowns across four eye-care pharmaceutical stocks. | · | tweet ↗ |
| 2026-10-06 | @PrismDM | +0.10 | OKYO enrolled the first patients in a Phase 3 trial, with no efficacy data yet. | · | tweet ↗ |
| 2026-10-06 | @PrismMarketView | +0.10 | OKYO enrolled the first patients in its pivotal Phase 3 trial. | · | tweet ↗ |
| 2026-10-06 | @proactive_x | +0.30 | OKYO Pharma began the Phase 3 NEPTUNE trial of urcosimod. | · | tweet ↗ |
| 2026-10-06 | @proactive_x | +0.35 | OKYO enrolled the first patients in a Phase 3 neuropathic corneal pain trial. | · | tweet ↗ |
| 2026-10-06 | @CrweWorld | +0.25 | OKYO enrolled the first patients in a Phase 3 pivotal trial of urcosimod. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.